Initiator Pharma (INIT) Q2 2024 earnings summary

Executive summary

• Advanced pudafensine with new international patent application for ED dosage regime, extending protection until 2044 and supporting further clinical development.

• Published preclinical pharmacology results for pudafensine in the British Journal of Pharmacology, validating its mechanism of action.

• Focused on moderate to severe ED patients, with strong Phase IIb efficacy data supporting further development toward market authorization.

• Ongoing business development activities and growing interest in the Sexual Health Franchise, including Female Sexual Dysfunction (FSD).

Financial highlights

• No revenue generated in Q2 or H1 2024.

• Q2 2024 operating loss of KDKK 4,991, improved from KDKK 8,882 in Q2 2023; H1 2024 operating loss KDKK 8,568, down from KDKK 17,559 year-over-year.

• Net loss after tax for Q2 2024 was KDKK 4,786 (Q2 2023: KDKK 10,422); H1 2024 net loss KDKK 8,909 (H1 2023: KDKK 19,689).

• Cash and cash equivalents at June 30, 2024: KDKK 14,487 (Dec 31, 2023: KDKK 24,336).

• Equity at June 30, 2024: KDKK 18,916 (Dec 31, 2023: KDKK 11,162), reflecting conversion of MAC Clinical Research receivable.

Outlook and guidance

• Anticipates further clinical development of pudafensine, including Phase III studies for ED and potential regulatory submissions.

• Expects continued business development and partnering activities, especially in the FSD segment.